Drugs / Fibrinogen Concentrate
Fibrinogen Concentrate
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02528708 | Jan → Dec 2021 | — | Yale University | Withdrawn | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03508141 | Jul 2018 → Jun 2021 | blood coagulation disease, hemorrhagic disease | Gold Coast Hospital and Health Service | Unknown | No outcome recorded |
| Phase 2 | NCT04807621 | Mar 2018 → Jan 2022 | congenital heart disease | Sahlgrenska University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02745041 | Dec 2016 → Jan 2018 | blood coagulation disease, hemorrhagic disease | Gold Coast Hospital and Health Service | Completed | No outcome recorded |
| Phase 2 | NCT02542306 | Jul 2013 → Aug 2016 | aortic disorder | Hongjia Zhang | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05449834 | Nov 2022 → Jun 2026 overdue | blood coagulation disease | Australian and New Zealand Intensive Care Research Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT03932240 | Aug 2019 → Apr 2021 | vascular hemostatic disease | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT04111822 | Oct 2018 → Oct 2020 | infectious disease with sepsis | Cristina Martinez | Completed | No outcome recorded |
| Phase 43 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT02864875 | Dec 2015 → Jan 2017 | acquired coagulation factor deficiency | University of Sao Paulo General Hospital | Completed | Met primary |
| Phase 4 | NCT02155725 | Apr 2014 → Aug 2018 | — | LFB | Completed | Missed primary |
| Phase 4 | NCT00994045 | Jun 2010 → Aug 2013 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06582420 | Jan → Aug 2025 overdue | — | Unidade Local de Saude do Arco Ribeirinho | Not yet recruiting | No outcome recorded |
| — | NCT03801135 | Oct 2018 → Sep 2019 | Guillain-Barre syndrome, Miller Fisher syndrome, anti-glomerular basement membrane disease, chronic inflammatory demyelinating polyradiculoneuropathy +2 | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT01475344 Comparator | Sep 2011 → Oct 2015 | — | Medical University Innsbruck | Completed | No outcome recorded |
| Phase 2 | NCT01187225 Comparator | Aug 2010 → Jan 2011 | blood coagulation disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT04149171 Comparator | Sep 2018 → Dec 2020 | — | Cristina Martinez | Completed | No outcome recorded |
| Phase 3 | NCT01545635 Comparator | Mar 2012 → Feb 2016 | brain injury | Medical University Innsbruck | Terminated | No outcome recorded |
| Phase 4 | NCT03884725 Comparator | Mar → Jun 2019 | coagulation protein disease | Filomena R B G Galas | Unknown | No outcome recorded |
| Phase 4 | NCT03014700 Comparator | Mar 2016 → Apr 2018 | congenital heart disease | Stanford University | Completed | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrinogen Concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02745041 ↗ |
| Known as | Haemocomplettan P | “Fibrinogen concentrate (Haemocomplettan P)may reduce perioperative bleeding, requirements of blood transfusion and clinical outcomes in children undergoing cardiac surgery with...” NCT01187225 ↗1“Fibrinogen concentrate (Haemocomplettan P)may reduce perioperative bleeding, requirements of blood transfusion and clinical outcomes in children undergoing cardiac surgery with pump.” NCT03884725 ↗ |
| Known as | Human Fibrinogen concentrate | “Drug: Human Fibrinogen concentrate” NCT02155725 ↗1“Drug: Human Fibrinogen Concentrate” NCT01475344 ↗ |
| Action | Restore | “Early fibrinogen replacement is recommended by several international trauma guidelines using either fibrinogen concentrate (FC) or cryoprecipitate (Cryo).” PMID 28549445 ↗ May 2017 |
| Modality | Protein / enzyme biologic | “human fibrinogen concentrate” NCT02155725 ↗ |
| Route | Intravenous | “intravenous infusion over 5 min/vial” NCT01475344 ↗ |